•Systemic lupus erythematosus
•Type 1 diabetes
Inflammatory Bowel Disease
CrownBio provides well-characterized in vivo models to help clients understand the preclinical efficacy of their Crohn’s disease (CD) and ulcerative colitis (UC) agents, allowing the translation of their IBD therapeutics into the clinic. CrownBio’s portfolio features established preclinical models with diverse mechanisms capturing the distinct clinical and pathological features of IBD. This includes chemical induction of IBD through acute and chronic dextran sodium sulfate models to study UC-like disease, alongside an adoptive T cell transfer model for studying T cell driven UC and CD.
Clients use the rheumatoid arthritis models to determine efficacy and response to treatment, and improve the selection of their next qualified lead agent. Crownbio’s collagen antibody-induced arthritis (CAIA) or collagen-induced arthritis (CIA) mouse models capture the key characteristics of clinical and pathological rheumatoid arthritis.
Systemic Lupus Erythematosus
CrownBio’s robust in vivo models more closely represent human systemic lupus erythematosus, enabling effective advancement of novel therapeutic agents. CrownBio’s provide models with diverse mechanisms capturing many key characteristic clinical and pathological features of systemic lupus erythematosus in the spontaneous MRL/Faslpr or NZB/W models.
Crownbio’s validated peritonitis models recapitulate acute inflammation, and are used to effectively progress anti-inflammatory agents. For a simple and rapid evaluation of agent inflammasome-mediated acute inflammatory response, clients choose the monosodium urate(MSU)-induced “gout” peritonitis model, with a Zymosan-induced peritonitis model available to assess an agents ability to attenuate acute TLR-activated inflammation associated with peritonitis.
Type 1 Diabetes
CrownBio provides well-established and reliable models of spontaneous and accelerated T1D to maximize the translatability of Type 1 diabetes preclinical research. Agents can be assessed using a simple, spontaneous T1D model in the non-obese diabetic (NOD) mouse which has no confounding immune modulation due to induction reagents, or with accelerated T1D development in this model through the addition of cyclophosphamide.
For more information about inflammation, check out:
For any enquires, please contact us
Tags: Atlantis Bioscience, Biomarker discovery, CRO, Crown Bioscience, CrownBio, DMPK, drug development, drug discovery, homograft, Hubrecht Organoid Technology, humanised models, immuno-oncology, OmniScreen, organoids, Orthotopic Models, patient derived xenograft, PDX, pharmacokinetic, Preclinical Oncology, syngeneic models